RU2008125197A - Фармацевтические композиции - Google Patents
Фармацевтические композиции Download PDFInfo
- Publication number
- RU2008125197A RU2008125197A RU2008125197/15A RU2008125197A RU2008125197A RU 2008125197 A RU2008125197 A RU 2008125197A RU 2008125197/15 A RU2008125197/15 A RU 2008125197/15A RU 2008125197 A RU2008125197 A RU 2008125197A RU 2008125197 A RU2008125197 A RU 2008125197A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- parts
- azd2171
- excipient
- plastic filler
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 35
- 239000004033 plastic Substances 0.000 claims abstract 37
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 31
- 239000000945 filler Substances 0.000 claims abstract 28
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 claims abstract 25
- 229960002412 cediranib Drugs 0.000 claims abstract 25
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract 22
- 239000008101 lactose Substances 0.000 claims abstract 22
- 150000003839 salts Chemical class 0.000 claims abstract 20
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract 4
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 claims abstract 4
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims abstract 4
- 235000019700 dicalcium phosphate Nutrition 0.000 claims abstract 4
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 claims abstract 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract 3
- 229930195725 Mannitol Natural products 0.000 claims abstract 3
- 239000000594 mannitol Substances 0.000 claims abstract 3
- 235000010355 mannitol Nutrition 0.000 claims abstract 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims abstract 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000008187 granular material Substances 0.000 claims 4
- 239000008240 homogeneous mixture Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000007884 disintegrant Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 239000011230 binding agent Substances 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- JRMGHBVACUJCRP-BTJKTKAUSA-N (z)-but-2-enedioic acid;4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline Chemical class OC(=O)\C=C/C(O)=O.COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 JRMGHBVACUJCRP-BTJKTKAUSA-N 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0523810.0 | 2005-11-23 | ||
| GBGB0523810.0A GB0523810D0 (en) | 2005-11-23 | 2005-11-23 | Pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008125197A true RU2008125197A (ru) | 2009-12-27 |
Family
ID=35601030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008125197/15A RU2008125197A (ru) | 2005-11-23 | 2006-11-21 | Фармацевтические композиции |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20090028943A1 (enExample) |
| EP (2) | EP2283828A1 (enExample) |
| JP (1) | JP2009516726A (enExample) |
| KR (1) | KR20080070056A (enExample) |
| CN (2) | CN102327267A (enExample) |
| AR (1) | AR057928A1 (enExample) |
| AU (1) | AU2006318946A1 (enExample) |
| BR (1) | BRPI0618906A2 (enExample) |
| CA (1) | CA2628917A1 (enExample) |
| EC (1) | ECSP088555A (enExample) |
| GB (1) | GB0523810D0 (enExample) |
| NO (1) | NO20082097L (enExample) |
| RU (1) | RU2008125197A (enExample) |
| TW (1) | TW200735875A (enExample) |
| UY (1) | UY29952A1 (enExample) |
| WO (1) | WO2007060402A1 (enExample) |
| ZA (1) | ZA200804103B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0017548B8 (pt) * | 1999-02-10 | 2023-05-02 | Astrazeneca Ab | Composto |
| GB0330002D0 (en) | 2003-12-24 | 2004-01-28 | Astrazeneca Ab | Quinazoline derivatives |
| RU2519768C2 (ru) * | 2008-06-20 | 2014-06-20 | Мерк Патент Гмбх | Поддающаяся прямому прессованию и быстро распадающаяся матрица таблетки |
| WO2010005527A1 (en) | 2008-06-30 | 2010-01-14 | Angioblast Systems, Inc. | Treatment of eye diseases and excessive neovascularization using a combined therapy |
| TW201129386A (en) * | 2009-11-05 | 2011-09-01 | Fmc Corp | Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients |
| WO2013059740A1 (en) | 2011-10-21 | 2013-04-25 | Foundation Medicine, Inc. | Novel alk and ntrk1 fusion molecules and uses thereof |
| EP4223770A3 (en) | 2012-11-05 | 2023-10-18 | Foundation Medicine, Inc. | Novel fusion molecules and uses thereof |
| HK1214830A1 (zh) | 2012-11-05 | 2016-08-05 | Foundation Medicine, Inc. | 新型ntrk1融合分子及其应用 |
| EP3939614A1 (en) | 2013-01-18 | 2022-01-19 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
| KR20220164069A (ko) | 2013-06-06 | 2022-12-12 | 피브로겐, 인크. | Hif 하이드록실라제 억제자의 약학적 제형 |
| CA3012718A1 (en) | 2016-02-08 | 2017-08-17 | Vitrisa Therapeutics, Inc. | Compositions with improved intravitreal half-life and uses thereof |
| PE20221838A1 (es) * | 2020-04-24 | 2022-11-29 | Astrazeneca Ab | Formulaciones farmaceuticas |
| CN115400136B (zh) * | 2022-07-22 | 2023-10-03 | 江苏亚邦爱普森药业有限公司 | 一种克拉霉素固体制剂及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0017548B8 (pt) | 1999-02-10 | 2023-05-02 | Astrazeneca Ab | Composto |
| ES2292414T3 (es) * | 2000-07-27 | 2008-03-16 | Roquette Freres | Granulos a base de almidon y de lactosa. |
| SE0101329D0 (sv) * | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Pharmaceutical formulation |
| CA2363528A1 (en) * | 2001-11-19 | 2003-05-19 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Immediate release tablet containing naproxen sodium |
| CN1625555A (zh) * | 2002-02-01 | 2005-06-08 | 阿斯特拉曾尼卡有限公司 | 喹唑啉化合物 |
| AU2003245313A1 (en) * | 2002-06-10 | 2003-12-22 | Elan Pharma International, Ltd | Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (statins), novel combinations thereof as well as manufacturing of these pharmaceutical compositions |
| US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| GB0330002D0 (en) * | 2003-12-24 | 2004-01-28 | Astrazeneca Ab | Quinazoline derivatives |
-
2005
- 2005-11-23 GB GBGB0523810.0A patent/GB0523810D0/en not_active Ceased
-
2006
- 2006-11-17 TW TW095142644A patent/TW200735875A/zh unknown
- 2006-11-21 CN CN2011102142130A patent/CN102327267A/zh active Pending
- 2006-11-21 EP EP10182729A patent/EP2283828A1/en not_active Withdrawn
- 2006-11-21 KR KR1020087013620A patent/KR20080070056A/ko not_active Withdrawn
- 2006-11-21 BR BRPI0618906-7A patent/BRPI0618906A2/pt not_active IP Right Cessation
- 2006-11-21 WO PCT/GB2006/004320 patent/WO2007060402A1/en not_active Ceased
- 2006-11-21 US US12/094,702 patent/US20090028943A1/en not_active Abandoned
- 2006-11-21 EP EP06808603A patent/EP1954247A1/en not_active Withdrawn
- 2006-11-21 JP JP2008541808A patent/JP2009516726A/ja active Pending
- 2006-11-21 RU RU2008125197/15A patent/RU2008125197A/ru not_active Application Discontinuation
- 2006-11-21 AU AU2006318946A patent/AU2006318946A1/en not_active Abandoned
- 2006-11-21 CN CN200680043657XA patent/CN101312715B/zh not_active Expired - Fee Related
- 2006-11-21 CA CA002628917A patent/CA2628917A1/en not_active Abandoned
- 2006-11-22 UY UY29952A patent/UY29952A1/es unknown
- 2006-11-23 AR ARP060105180A patent/AR057928A1/es unknown
-
2008
- 2008-05-06 NO NO20082097A patent/NO20082097L/no not_active Application Discontinuation
- 2008-05-13 ZA ZA200804103A patent/ZA200804103B/xx unknown
- 2008-06-18 EC EC2008008555A patent/ECSP088555A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0618906A2 (pt) | 2013-01-08 |
| KR20080070056A (ko) | 2008-07-29 |
| CN101312715A (zh) | 2008-11-26 |
| AU2006318946A1 (en) | 2007-05-31 |
| CA2628917A1 (en) | 2007-05-31 |
| ZA200804103B (en) | 2009-10-28 |
| UY29952A1 (es) | 2007-06-29 |
| TW200735875A (en) | 2007-10-01 |
| EP1954247A1 (en) | 2008-08-13 |
| EP2283828A1 (en) | 2011-02-16 |
| CN101312715B (zh) | 2011-12-14 |
| AR057928A1 (es) | 2007-12-26 |
| WO2007060402A1 (en) | 2007-05-31 |
| GB0523810D0 (en) | 2006-01-04 |
| NO20082097L (no) | 2008-08-18 |
| CN102327267A (zh) | 2012-01-25 |
| US20090028943A1 (en) | 2009-01-29 |
| JP2009516726A (ja) | 2009-04-23 |
| ECSP088555A (es) | 2008-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008125197A (ru) | Фармацевтические композиции | |
| KR20190013723A (ko) | 팔보시클립의 약학 제제 및 그 제조 방법 | |
| RU2004122631A (ru) | Фармацевтические композиции, содержащие частичный агонист 5- нт4 | |
| EP3384901A1 (en) | Pharmaceutical composition comprising lenvatinib mesylate | |
| JP2012001473A5 (enExample) | ||
| IS7398A (is) | Lyfjablanda sem felur í sér N-((1-N-bútýl-4-píperídínýl)metýl)-3,4-díhýdró-2H-(1,3)oxasínó(3,2-A)indól-10-karboxamíð eða salt og aðferð þar að lútandi sem felur í sér þurrkornamyndun | |
| JP2009516726A5 (enExample) | ||
| ES2822104T3 (es) | Procedimiento para la preparación de un coadyuvante de tableteado, así como coadyuvante de tableteado | |
| CA2696977A1 (en) | Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof | |
| EP3860606A1 (en) | Pharmaceutical composition comprising lenvatinib esylate or tosylate | |
| HRP20161602T1 (hr) | Postupak priprave čvrstog farmaceutskog pripravka | |
| WO2006078948A3 (en) | Stable pharmaceutical formulations of zonisamide and methods for their manufacture | |
| CN103142525A (zh) | 奥氮平胃溶型片剂及其制备方法 | |
| CN102846573B (zh) | 水飞蓟宾双层缓释片及其制备方法 | |
| KR20100083047A (ko) | 생체이용률이 향상된 발사르탄을 포함하는 약제학적 조성물 | |
| CN103330692A (zh) | 提高稳定性的辛伐他汀组分及其制备方法 | |
| JP4774739B2 (ja) | 漢方エキス含有錠剤組成物およびその製造方法 | |
| RU2006119505A (ru) | Стабилизированная композиция азитромицина | |
| IL182549A (en) | Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby | |
| RU2183119C1 (ru) | Фармацевтическая композиция, обладающая спазмолитической активностью, способ ее получения | |
| WO2016024291A1 (en) | Linaclotide stable composition | |
| SK9912003A3 (en) | Pharmaceutical composition containing citalopram | |
| KR101509489B1 (ko) | 발사르탄을 함유하는 고형 경구제형의 제조 방법 | |
| KR101244414B1 (ko) | 고함량 이반드론산 함유 골다공증 예방 또는 치료용 조성물 및 이의 제조방법 | |
| CN102652748B (zh) | 稳定的艾夫他滨药物组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20100112 |